BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström's MacroglobulinemiaBusiness Wire • 11/23/21
BeiGene Launches Proposed Initial Public Offering on the STAR Market in ChinaBusiness Wire • 11/23/21
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D CenterBusiness Wire • 11/23/21
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339Business Wire • 11/22/21
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell LymphomaBusiness Wire • 11/15/21
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual MeetingBusiness Wire • 11/04/21
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell LymphomaBusiness Wire • 10/20/21
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell LymphomaBusiness Wire • 10/10/21
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in AustraliaBusiness Wire • 10/10/21
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström's MacroglobulinemiaBusiness Wire • 10/07/21
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström's MacroglobulinemiaBusiness Wire • 09/17/21
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone LymphomaBusiness Wire • 09/15/21
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell CarcinomaBusiness Wire • 09/13/21
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021Business Wire • 09/12/21